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In March 2020, the World Health Organization (WHO) declared the
2019 novel coronavirus (severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2)) and its associated disease (coronavirus disease 2019 (COVID-19)) a pandemic. With the rapid spread
of COVID-19, there has been gradual recognition of its pathogenesis and clinical characteristics based largely on adult studies.
Information on clinical presentation, evaluation and treatment of
COVID-19 in children remains limited. We aim to highlight key
ﬁndings from recent studies to provide clinical pearls for
pediatricians caring for children with suspected COVID-19.
CLINICAL PEARL 1: DESPITE RELATIVELY MILD ILLNESS
SEVERITY, PROVIDERS MUST BE AWARE OF NOVEL
INFLAMMATORY SYNDROMES IN CHILDREN
A report from the Centers for Disease Control and Prevention
(CDC) of 2572 laboratory-conﬁrmed COVID-19 cases suggests that
most children in the United States remain asymptomatic or
experience mild symptoms.1 Children <18 years of age accounted
for <2% of cases. Of these, 6% required hospitalization and only
2% required intensive care. The exact reason behind milder illness
severity in children is currently unclear.
However, since April 2020, there have been increasing reports of
children with SARS-CoV-2 infection presenting with inﬂammatory
features similar to Kawasaki disease.2,3 This has recently
been termed as multisystem inﬂammatory syndrome in children
(MIS-C). The CDC case deﬁnition for MIS-C includes (1) persistent
fever ≥38.0 °C; (2) laboratory evidence of inﬂammation; (3)
evidence of clinically severe disease requiring hospitalization; (4)
multisystem (≥2) organ involvement; (5) positive for current or
recent SARS-CoV-2 infection; and (6) no alternative plausible
diagnoses.2 A retrospective study of 58 children in England who
met criteria for MIS-C found that all children presented with fever,
31% with abdominal pain, 52% with diarrhea, 52% with an
erythematous rash, 45% with conjunctival injection, 29% with
mucous membrane changes, 26% with vomiting, 16% with
lymphadenopathy, and 16% with swollen extremities.4 Similar to
Kawasaki disease, echocardiogram ﬁndings in children with MIS-C
include myocardial dysfunction (31%), coronary artery aneurysms
(15%), and dilatations (13%). However, this study also found
children with MIS-C to be older than those with Kawasaki disease
(mean age of 9 vs 3 years) and to have higher neutrophil count,
C-reactive peptide, ferritin, troponin, and N-terminal pro-B-type
natriuretic peptide values. This may suggest that this novel
syndrome be considered a separate entity from other pediatric
inﬂammatory disorders.
The mechanism underlying MIS-C is unclear. It is currently
believed to be an aberrant acquired immune response to SARSCoV-2 with developed antibodies triggering this inﬂammatory
process.4 This likely explains why most affected children have

positive antibody testing despite a negative PCR test. Children
with MIS-C have been treated with intravenous immunoglobulin,
aspirin, corticosteroids, and/or immunomodulators.4,5 Although
most children recover well, pediatricians must remain on high
alert as up to one-half of these children may develop shock
requiring admission to intensive care units for inotropic support.4,6
In addition, an interesting cutaneous manifestation has been
described in children with COVID-19. A case series from Spain
described 22 pediatric patients presenting with acral erythematoviolaceous purpuric lesions consistent with chilblains or pernio.7
These lesions were all located on the toes and lateral aspects of
the feet and have been popularly dubbed “COVID toes” in the
media. The lesions are typically non-tender and non-pruritic. To a
lesser extent, they can also be located on the periumbilical areas
of the ﬁngers. Most of these lesions spontaneously resolve
3–5 weeks after onset.
CLINICAL PEARL 2: CLINICAL PRESENTATION, LABORATORY
INVESTIGATIONS, AND RADIOLOGIC FINDINGS IN CHILDREN
DIFFER FROM ADULTS
A US report of 291 children with conﬁrmed COVID-19 found that
the most common symptoms were fever (56%) and cough (54%).1
Nearly one-third of children had gastrointestinal complaints of
abdominal pain, nausea/vomiting, and diarrhea. Other nonspeciﬁc symptoms included rhinorrhea, sore throat, headache,
and myalgia. These ﬁgures vary greatly from adults in the same
report, in whom fever and cough were reported in 71% and 80%
of patients, respectively.
Laboratory investigations of 20 infected children from the Wuhan
Children’s Hospital found 90% of children having a normal or low
white blood cell count, which may be increased in adult patients.8
Other pediatric studies report normal inﬂammatory markers
including C-reactive protein, procalcitonin, and ferritin.9 These
indicate a lack of immune dysregulation that is more commonly
seen in adults and may provide another explanation for milder
disease severity in children. An exception is the MIS-C presentation
likely due to a dysregulated inﬂammatory response, which is
characterized by signiﬁcantly elevated inﬂammatory markers.4
In cases of severe disease in children necessitating hospital
admission, computed tomography (CT) of the chest may be useful
to provide more information. The most common CT ﬁndings in the
pediatric population include unilateral and bilateral subpleural
ground-glass opacities and consolidation with a surrounding halo
sign.8 The halo sign is not routinely seen in CT images from adult
patients and is suggested to be a “characteristic ﬁnding” in
affected children. There has been more new interest in the use of
lung ultrasound given its beneﬁts of being radiation-free and
portable, which would limit patient transport within the hospital
and minimize exposure to other patients and staff.10 Lung
ultrasound ﬁndings in children include subpleural consolidations
and interstitial B lines. Further, improvements in these parameters
were seen on repeat ultrasound prior to discharge, which may
suggest its utility in real-time assessment of recovering patients.
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CLINICAL PEARL 3: NEONATES ARE AT A GREATER RISK OF
SEVERE ILLNESS AND REQUIRE SPECIAL CONSIDERATIONS
Although children overall are less affected by COVID-19, very
young infants are more vulnerable to the disease. The largest
retrospective study of 731 Chinese children with conﬁrmed
COVID-19 found that 54% of all children with critical severity of
illness were <1 year of age.11 In the US, neonates account for 15%
of all pediatric cases.1 Therefore, special attention should be given
to those in the neonatal setting. Clinicians caring for neonates
should be aware that there is currently no evidence to suggest
vertical transmission or prenatal infection of COVID-19 from
infected mothers to neonates.12 The transmission of SARS-CoV-2
to neonates is thought to be postnatal from infected mothers and
other close contacts.13 Clinical signs include fever, lethargy,
increased work of breathing, vomiting, diarrhea, and feeding
intolerance. Preterm infants infected with SARS-CoV-2 have also
been reported in whom COVID-19 manifestations are difﬁcult to
distinguish from prematurity-related respiratory comorbidities.14
The CDC currently recommends that all infants, including those
who are asymptomatic, born to mothers with conﬁrmed or
suspected COVID-19 be tested at approximately 24 h of age.13
Pending the result, these infants should be presumed infectious
and remain isolated from other neonates. The CDC does not
prohibit infected mothers from breastfeeding their newborns as
long as mothers follow appropriate respiratory etiquette. Wellappearing neonates can be carefully discharged while awaiting
results of the SARS-CoV-2 testing.
CLINICAL PEARL 4: WITH THE REOPENING OF PUBLIC AREAS
AND SCHOOLS, PROVIDERS MUST CONTINUE TO FOCUS ON
KEEPING CHILDREN HEALTHY AND RESILIENT
As in adults, the COVID-19 outbreak and its lockdown has been
extremely disruptive to children’s daily routines. There is some
evidence that school closure for children may be minimally
impactful in reducing spread of COVID-19 and may in fact be
harmful.15 The stay-at-home orders have led to reduced access to
social support services for children and their families.16 These
include children who socialize with their friends and peers at
school as coping mechanisms for everyday problems and those
children with special education needs who rely on close therapist
contact to develop essential skills.17 Conversely, parents have
been tasked with additional responsibilities, including facilitating
online learning that can stress families as a whole. As restrictions
on school closures and community services begin to loosen,
pediatricians must continue to work with families to ensure
children emerge healthy and resilient. Strategies include encouraging families to plan daily schedules to limit children’s screen time
and incorporate regular physical activity and exercise.18 Further,
physical distancing rather than social distancing should be
promoted to allow children and their families to remain socially
connected with loved ones. Parents should also be educated on
how their child may display signs of stress including irregular
sleeping habits, dietary habits, difﬁculty with attention and
concentration, and excessive worrying or sadness. Encourage
parents to talk honestly but positively about the pandemic in ways
that their child can understand and to seek help when needed.
A recent study from China found that 96% of children with
COVID-19 were household contacts of adults who displayed
symptoms of the infection earlier.19 Hence, the most common
exposure history in children to the SARS-CoV-2 virus is through
family clustering. Therefore, pediatricians must remain on high
alert for children in households where family members have been
diagnosed with COVID-19 even though the child may be initially
asymptomatic. Conversely, it was originally thought that infected
children who appear asymptomatic may play a signiﬁcant role
propagating community spread. However, evidence does not lean
toward children being a major vector for disease spread.20 This
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provides some reassurance that school-based transmission could
be managed in the upcoming months as schools reopen. To
further lessen the risk of transmission with the reopening of
schools, hygiene etiquette with frequent handwashing must
remain a priority for families and care providers. Lastly, 40–50%
of all children with COVID-19 can be co-infected with other
respiratory pathogens.8,19 Heading into the “ﬂu season” later this
year, it will be important for pediatricians to consider SARS-CoV-2
co-infection in children with more common pathogens, such as
the respiratory syncytial virus.
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